RU2706708C2 - Твердые лекарственные формы ондансетрона с пролонгированным высвобождением для лечения симптомов тошноты, рвоты и диареи - Google Patents

Твердые лекарственные формы ондансетрона с пролонгированным высвобождением для лечения симптомов тошноты, рвоты и диареи Download PDF

Info

Publication number
RU2706708C2
RU2706708C2 RU2016139474A RU2016139474A RU2706708C2 RU 2706708 C2 RU2706708 C2 RU 2706708C2 RU 2016139474 A RU2016139474 A RU 2016139474A RU 2016139474 A RU2016139474 A RU 2016139474A RU 2706708 C2 RU2706708 C2 RU 2706708C2
Authority
RU
Russia
Prior art keywords
ondansetron
release
amount
tablet
hypromellose
Prior art date
Application number
RU2016139474A
Other languages
English (en)
Russian (ru)
Other versions
RU2016139474A (ru
RU2016139474A3 (cg-RX-API-DMAC7.html
Inventor
Реза Фатхи
Гилеад РАДАЙ
Гай ГОЛДБЕРГ
Original Assignee
Редхилл Байофарма Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54067752&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2706708(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Редхилл Байофарма Лтд. filed Critical Редхилл Байофарма Лтд.
Publication of RU2016139474A publication Critical patent/RU2016139474A/ru
Publication of RU2016139474A3 publication Critical patent/RU2016139474A3/ru
Application granted granted Critical
Publication of RU2706708C2 publication Critical patent/RU2706708C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2016139474A 2014-03-11 2015-03-11 Твердые лекарственные формы ондансетрона с пролонгированным высвобождением для лечения симптомов тошноты, рвоты и диареи RU2706708C2 (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461951092P 2014-03-11 2014-03-11
US201461951074P 2014-03-11 2014-03-11
US201461951112P 2014-03-11 2014-03-11
US61/951,112 2014-03-11
US61/951,092 2014-03-11
US61/951,074 2014-03-11
US201462040136P 2014-08-21 2014-08-21
US62/040,136 2014-08-21
PCT/IB2015/000997 WO2015136377A2 (en) 2014-03-11 2015-03-11 Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms

Publications (3)

Publication Number Publication Date
RU2016139474A RU2016139474A (ru) 2018-04-11
RU2016139474A3 RU2016139474A3 (cg-RX-API-DMAC7.html) 2018-10-26
RU2706708C2 true RU2706708C2 (ru) 2019-11-20

Family

ID=54067752

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016139474A RU2706708C2 (ru) 2014-03-11 2015-03-11 Твердые лекарственные формы ондансетрона с пролонгированным высвобождением для лечения симптомов тошноты, рвоты и диареи

Country Status (17)

Country Link
US (3) US9675588B2 (cg-RX-API-DMAC7.html)
EP (1) EP3116500B1 (cg-RX-API-DMAC7.html)
JP (1) JP6461186B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160132057A (cg-RX-API-DMAC7.html)
CN (1) CN106456611B (cg-RX-API-DMAC7.html)
AU (1) AU2015228545B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016020877B1 (cg-RX-API-DMAC7.html)
CA (1) CA2941829C (cg-RX-API-DMAC7.html)
CL (1) CL2016002251A1 (cg-RX-API-DMAC7.html)
IL (1) IL247698B (cg-RX-API-DMAC7.html)
MX (1) MX373002B (cg-RX-API-DMAC7.html)
PH (1) PH12016501756B1 (cg-RX-API-DMAC7.html)
RU (1) RU2706708C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201607511WA (cg-RX-API-DMAC7.html)
UA (1) UA121209C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015136377A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201606276B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2818947C1 (ru) * 2023-05-15 2024-05-07 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева" Министерства здравоохранения Российской Федерации Способ профилактики и лечения тошноты и рвоты у детей и подростков, получающих высокоэметогенную химиотерапию

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180014778A (ko) 2015-06-03 2018-02-09 트리아스텍 인코포레이티드 제형 및 이의 용도
CA3051614A1 (en) 2017-01-26 2018-08-02 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
JP7315383B2 (ja) * 2019-06-27 2023-07-26 株式会社Ｓｃｒｅｅｎホールディングス インクジェット用水性組成物及び固体製剤
WO2023102491A1 (en) * 2021-12-01 2023-06-08 Invea Therapeutics, Inc. Methods for treating gastrointestinal inflammatory disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080200508A1 (en) * 2004-12-20 2008-08-21 Collegium Pharmaceutical, Inc. Pharmaceutical Compositions For Sleep Disorders
WO2009118763A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Multilayered pharmaceutical compositions and processes thereof
RU2490012C2 (ru) * 2006-01-27 2013-08-20 Апталис Фарматех Инк Системы доставки лекарственного средства, содержащие слабощелочной селективный 5-ht3, серотониновый блокатор и органические кислоты

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4720353A (en) 1987-04-14 1988-01-19 Richardson-Vicks Inc. Stable pharmaceutical w/o emulsion composition
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
BE1011045A3 (fr) 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
US6090411A (en) 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US6733789B1 (en) 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
DE60019334T2 (de) 1999-12-09 2005-09-08 Alza Corp., Mountain View Antivirale arznei
WO2003024427A1 (en) 1999-12-20 2003-03-27 Temple University Of The Commonwealth System Of Higher Education Tableted oral extended release dosage form
US6936275B2 (en) 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
US20020044962A1 (en) 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US20020172712A1 (en) 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
GB0119012D0 (en) 2001-08-03 2001-09-26 Strakan Group Plc Transdermal delivery of drugs
US20050131045A1 (en) 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
US7704527B2 (en) 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
PL378369A1 (pl) * 2003-01-13 2006-04-03 Dynogen Pharmaceuticals, Inc. Sposób leczenia mdłości, wymiotów, nudności lub ich dowolnej kombinacji
PL1683526T3 (pl) * 2003-11-14 2012-09-28 Senju Pharma Co Preparat wodnego roztworu zawierający antybiotyk aminoglikozydowy i bromfenak
CA2635313C (en) 2005-12-29 2013-12-31 Osmotica Corp. Triple combination release multi-layered tablet
US20070190141A1 (en) 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20080004260A1 (en) 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
BRPI0621996B8 (pt) * 2006-08-18 2022-07-05 Evonik Roehm Gmbh preparação farmacêutica compreendendo um núcleo com um ingrediente ativo e com um ácido orgânico e/ou com o sal de um ácido orgânico, e um revestimento que envolve o núcleo e que compreende um ou mais copolímeros de (met)acrilato, e seu uso.
CN100584319C (zh) 2006-10-16 2010-01-27 北京科信必成医药科技发展有限公司 群孔释放渗透泵控释片及其制备方法
MX2009004439A (es) 2006-10-25 2009-05-11 Mcneil Ppc Inc Composicion de ibuprofeno.
GB0624087D0 (en) 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
JP2010514679A (ja) 2006-12-22 2010-05-06 スリーエム イノベイティブ プロパティズ カンパニー 制御放出組成物及び方法
US20100196291A1 (en) 2009-01-30 2010-08-05 Laurence Halimi Personal care sunscreen compositions having reduced eye irritation
EP2403487A2 (en) 2009-03-04 2012-01-11 Fdc Limited Oral controlled release dosage forms for water soluble drugs
US20110003005A1 (en) 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US20110108058A1 (en) * 2009-11-11 2011-05-12 Axcelis Technologies, Inc. Method and apparatus for cleaning residue from an ion source component
AU2010343147A1 (en) 2009-12-28 2012-07-19 Monosol Rx, Llc Orally administrable film dosage forms containing ondansetron
WO2012028922A2 (en) 2010-08-30 2012-03-08 Lupin Limited Controlled release pharmaceutical compositions of milnacipran
US20120128730A1 (en) 2010-11-23 2012-05-24 Nipun Davar Compositions and methods for once-daily treatment of obsessive compulsive disorder with ondansetron
KR102270521B1 (ko) 2013-03-14 2021-06-30 레드힐 바이오파마 엘티디 구토억제 서방형 고체 제형

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080200508A1 (en) * 2004-12-20 2008-08-21 Collegium Pharmaceutical, Inc. Pharmaceutical Compositions For Sleep Disorders
RU2490012C2 (ru) * 2006-01-27 2013-08-20 Апталис Фарматех Инк Системы доставки лекарственного средства, содержащие слабощелочной селективный 5-ht3, серотониновый блокатор и органические кислоты
WO2009118763A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Multilayered pharmaceutical compositions and processes thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AL-ANSARI K. et al. Metoclopramide versus ondansetron for the treatment of vomiting in children with acute gastroenteritis. J.Pediatr. Gastroenterol Nutr. 2011 Aug; 53(2): 156-60 *
MAXTON DG et al. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? Aliment. Pharmacol. Ther. 1996 Aug; 10(4): 595-9. *
MAXTON DG et al. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? Aliment. Pharmacol. Ther. 1996 Aug; 10(4): 595-9. AL-ANSARI K. et al. Metoclopramide versus ondansetron for the treatment of vomiting in children with acute gastroenteritis. J.Pediatr. Gastroenterol Nutr. 2011 Aug; 53(2): 156-60 Реферат [он лайн] [найдено 24.10.2018] (найдено из интернет: www.ncbi.nlm.nih.gov/pubmed/21788756). *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2818947C1 (ru) * 2023-05-15 2024-05-07 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева" Министерства здравоохранения Российской Федерации Способ профилактики и лечения тошноты и рвоты у детей и подростков, получающих высокоэметогенную химиотерапию

Also Published As

Publication number Publication date
EP3116500B1 (en) 2023-09-13
AU2015228545B2 (en) 2020-03-12
ZA201606276B (en) 2019-04-24
CN106456611A (zh) 2017-02-22
US20150258029A1 (en) 2015-09-17
CA2941829A1 (en) 2015-09-17
EP3116500A2 (en) 2017-01-18
CA2941829C (en) 2021-11-02
MX373002B (es) 2020-04-30
JP6461186B2 (ja) 2019-01-30
CN106456611B (zh) 2021-07-20
BR112016020877A8 (pt) 2021-07-20
BR112016020877B1 (pt) 2022-11-29
IL247698B (en) 2020-08-31
RU2016139474A (ru) 2018-04-11
CL2016002251A1 (es) 2017-11-03
WO2015136377A2 (en) 2015-09-17
RU2016139474A3 (cg-RX-API-DMAC7.html) 2018-10-26
KR20160132057A (ko) 2016-11-16
SG11201607511WA (en) 2016-10-28
MX2016011734A (es) 2017-02-13
AU2015228545A1 (en) 2016-09-22
US20200253933A1 (en) 2020-08-13
BR112016020877A2 (pt) 2017-08-15
US20170258768A1 (en) 2017-09-14
UA121209C2 (uk) 2020-04-27
US9675588B2 (en) 2017-06-13
EP3116500A4 (en) 2017-10-25
WO2015136377A3 (en) 2016-01-14
JP2017507966A (ja) 2017-03-23
US10668050B2 (en) 2020-06-02
PH12016501756A1 (en) 2016-11-07
IL247698A0 (en) 2016-11-30
PH12016501756B1 (en) 2016-11-07

Similar Documents

Publication Publication Date Title
CN102387802B (zh) 包含羟考酮和纳洛酮的立即释放药物组合物
RU2467750C2 (ru) Ниацинсодержащие фармацевтическая композиция (варианты) и таблеточный препарат (варианты), способ снижения гиперемии и способ приготовления ниацинсодержащей таблетки
JP6566638B2 (ja) メサラミンの放出制御固形製剤
JP5052602B2 (ja) 制御用量薬物送達システム
RU2610435C2 (ru) Таблетка месалазина с улучшенной растворимостью
JP2014193878A (ja) トラネキサム酸製剤
US20200253933A1 (en) Methods for treating diarrhea predominant irritable bowel syndrome
JP6191883B2 (ja) 制御放出製剤
CA2971071A1 (en) Use of milrinone and derivatives thereof in the treatment of heart failure with preserved ejection fraction (hfpef)
JP6282676B2 (ja) 制吐作用のある徐放性固形製剤
US20150224056A1 (en) Pharmaceutical compositions of ibuprofen and famotidine
US20140322313A1 (en) Pharmaceutical compositions of ibuprofen and an h2 receptor antagonist
US20130236538A1 (en) Pharmaceutical compositions of ibuprofen and famotidine
HK1232432A1 (en) Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
HK1232432B (zh) 用於治疗恶心、呕吐或腹泻症状的恩丹西酮缓释固体制剂
HK1131888A (en) Low flush niacin formulation